Identification
- Summary
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is a component of a live attenuated influenza vaccine.
- Generic Name
- Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen
- DrugBank Accession Number
- DB16901
- Background
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen". This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde. Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Influenza A virus A/Norway/16606/2021 (H3N2)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetylsalicylic acid The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Acetylsalicylic acid. Aminosalicylic acid The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Aminosalicylic acid. Balsalazide The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Balsalazide. Bismuth subsalicylate The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Bismuth subsalicylate. Choline salicylate The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Choline salicylate. Diflunisal The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Diflunisal. Mesalazine The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Mesalazine. Methyl salicylate The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Methyl salicylate. Olsalazine The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Olsalazine. Phenyl aminosalicylate The risk or severity of Reye's syndrome can be increased when Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen is combined with Phenyl aminosalicylate. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FluMist Quadrivalent Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza A virus A/Victoria/1/2020 (H1N1) live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen (10000000 [FFU]/0.2mL) + Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen (10000000 [FFU]/0.2mL) Spray Nasal MedImmune, LLC 2022-08-08 2023-03-15 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Spray Nasal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 26, 2022 20:04 / Updated at December 01, 2022 11:32